B-CELL LYMPHOMA REFRACTORY
Clinical trials for B-CELL LYMPHOMA REFRACTORY explained in plain language.
Never miss a new study
Get alerted when new B-CELL LYMPHOMA REFRACTORY trials appear
Sign up with your email to follow new studies for B-CELL LYMPHOMA REFRACTORY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat brain lymphoma: drug combo enters human trials
Disease control Recruiting nowThis study tests a new drug, selinexor, added to standard chemotherapy for people with a type of blood cancer (B-cell lymphoma) that has come back or not responded to treatment and has spread to the brain. The goal is to see if the combination is safe and works better than curren…
Matched conditions: B-CELL LYMPHOMA REFRACTORY
Phase: PHASE1, PHASE2 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
New CAR T-Cell therapy targets tough lymphomas
Disease control Recruiting nowThis study tests a new type of CAR T-cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to target cancer cells. The goal is to find the best dose and see if it is safe and effectiv…
Matched conditions: B-CELL LYMPHOMA REFRACTORY
Phase: PHASE1, PHASE2 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
New CAR-T therapy trial targets tough blood cancers
Disease control Recruiting nowThis early-phase trial tests a personalized treatment where a patient's own immune cells are genetically modified to recognize and attack cancer cells. It is for children and adults with certain blood cancers (like leukemia or lymphoma) that have not responded to standard treatme…
Matched conditions: B-CELL LYMPHOMA REFRACTORY
Phase: PHASE1 • Sponsor: Nelson Hamerschlak • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
New mRNA CAR-T therapy aims to tackle tough blood cancers
Disease control Recruiting nowThis study tests a new type of CAR-T cell therapy that uses mRNA to target two proteins (CD19 and CD20) on cancer cells. It is for people with B-cell lymphoma or leukemia that has come back or not responded to treatment. The goal is to see if it is safe and effective, with up to …
Matched conditions: B-CELL LYMPHOMA REFRACTORY
Phase: PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Jun 11, 2026 12:10 UTC